Table I. Experimental design and outcome of ITV and challenge phases.
| Vaccination Phase (No. Infected/No. Vaccinated = % Infection) |
Challenge Phase (No Protected/No. Challenged = % Protection) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Experiment | Treatment | V1 | V2 | V3 | spz, 1 mo | spz, 3 mo | spz, 6 mo | iRBC, 1 mo |
| 1 | None | ND | 0/5 (0%) | |||||
| CQ | 10/10 (100%) | 0/10 (0%) | ||||||
| AS | 0/10 (0%) | 0/10 (0%) | ||||||
| 2 | None | ND | ND | 0/5 (0%) | ||||
| CQ | 10/10 (100%) | 0/10 (0%) | 9/10 (90%) | |||||
| AS | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) | |||||
| 3 | None | ND | ND | ND | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) | |
| CQ | 10/10 (100%) | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) | 5/5 (100%) | 5/5 (100%) | ||
| AS | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) | 5/5 (100%) | 5/5 (100%) | ||
| 4 | None | ND | ND | ND | 0/11 (0%) | |||
| CQ | 13/13 (100%) | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) | ||||
| AS | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) | ||||
For each experiment, the table indicates the drug used for the treatment (none, CQ, or AS) and the outcome of each course of ITV (V1, V2, and V3), both as the number and percentage of infected mice divided by the number of vaccinated mice, as well as the outcome of the challenge with spz or iRBCs 1, 3, or 6 mo, respectively, after the corresponding course of ITV, both as the number and the percentage of protected mice divided by the number of challenged mice.